10/03/2026
While our last update was certainly less than ideal, we want to continue keeping everyone in the loop. Kami started this journey wanting to be as transparent as possible, and we are sticking to that. ๐๏ธ๐ฉท
Her oncology team attempted to get her into the CAR-T trial at St. Jude and the TINKS trial at MD Anderson in Houston. However, both trials require two prior failed chemo attempts for eligibility. Itโs a frustrating hurdle, but we are pressing forward.
Her dad and I have spent countless hours researching and discussing next steps alongside her oncologist, who presented two chemo options:
1. Topotecan: Highly brutal, requiring frequent inpatient stays, blood transfusions, and severe neutropenia. We decided against putting her through this.
2. VCT (Vinorelbine + Cyclophosphamide + Temsirolimus): This is our chosen path. Research shows that Kamiโs specific cancerโPAX3-FOXO1 alveolar rhabdomyosarcomaโresponds very well to this combination.
To put things in perspective, only about 40 people per year are diagnosed with this exact genetic subtype. Out of billions, our girl is truly one of a kind! While her previous treatment (the RMS2021 trial) helped clear her chest, identifying this specific gene mutation now allows us to target what works best for her exact diagnosis instead of simply Rhabdomyosarcoma itself.
Unlike her previous treatment, which hit the cancer in heavy periodic intervals (causing her ups and downs), VCT is a low-dose, daily approach designed to keep constant, steady pressure on the tumors.
Kami will likely start VCT on Monday. We are also requesting a clear timeline from her care team to evaluate its effectiveness quickly so we know if/when trial eligibility becomes an option.
Please pray that VCT does its job and works effectively. Kami is an absolute warriorโsheโs handled this with so much grace that sheโs even supporting other young girls navigating the same battle!
Thank you all for your continuous love, prayers, and support! ๐๐๏ธ๐ฉท